Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04850495 · ClinicalTrials.gov registry record · Phase 1
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
A Phase 1 study, sponsored by Yazeed Sawalha.
- Active
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT04850495 is a Phase 1 study that is active but no longer recruiting, run by Yazeed Sawalha. The registered enrollment target is 38 participants.
The verdict
NCT04850495, a Phase 1 study, is active but no longer recruiting, sponsored by Yazeed Sawalha.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunotherapy regimen for DLBCL and is considered the standard-of-care treatment for patients with DLBCL. Three of the drugs in R-CHOP (cyclophosphamide, doxorubicin and vincristine) are chemotherapy drugs. Rituximab is a type of immunotherapy and prednisone is a type of steroids.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin Hydrochloride
- DRUG Prednisone
- BIOLOGICAL Rituximab
- DRUG Vincristine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04850495
The ClinicalTrials.gov registry entry for NCT04850495 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yazeed Sawalha, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04850495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04850495 about?
NCT04850495 is a clinical study titled "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma". This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase i...
What is the current status of trial NCT04850495?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2021-11-16. Estimated completion is 2026-12-15.
What interventions are being tested in trial NCT04850495?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin Hydrochloride (DRUG), Prednisone (DRUG), Rituximab (BIOLOGICAL), Vincristine Sulfate (DRUG).
Who is sponsoring clinical trial NCT04850495?
This trial is sponsored by Yazeed Sawalha, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.